NEW YORK (
CHANGE IN RATINGS
( AMLN) upgraded at Citigroup from Hold to Buy. $27 price target. Remain optimistic that the FDA will ultimately approve LAR.
( AMLN) price target raised at Barclays $2 to $24 on approval of drug Victoza. 2009 and 2010 EPS estimates set at -$1.25 and -$0.35, respectively. Maintain Overweight rating.
upgraded at UBS from Neutral to Buy. $46 price target. Stock is down 10% year-to-date, but should exceed better-than-expected production growth.
downgraded at Credit Suisse to Underperform from Neutral as underlying business is flat, and earnings expectations are weak. $36 price target. 2009 and 2010 EPS estimates set at $2.27 and $2.84, respectively.
upgraded at UBS from Neutral to Buy. $46 price target. Valuation call, as the stock is down 15% in recent weeks. Company also has a strong balance sheet.
upgraded at Credit Suisse to Outperform from Neutral as checks suggest near-term and long-term trends are improving. Company has excess cash. Price target jumped to $11.50 from $9.50.
( CXG) upgraded at UBS from Neutral to Buy. $34 price target. Reserves are up 34% year-over-year.
( CXPO) initiated at Barclays with an Overweight rating and $8 price target. Drilling results in the Haynesville Shale will drive shares. 2009 and 2010 EPS estimates set at -$1.45 and -$0.20, respectively.
target, estimate raised at Barclays. Barclays increased ETN price target to $69 from $62 after 4Q09 results beat. 2010 EPS estimate lifted to $4.05 from $3.55. Maintain Equal Weight rating.
estimates, target raised at UBS. ETN estimates were increased through 2011. Company has improving demand visibility. Sell rating and new $56 price target.
downgraded at UBS. JCI was downgraded from Buy to Neutral. Valuation call, based on a $32 price target. Estimates have largely caught up with the company's earnings potential.
initiated at Credit Suisse with an Outperform rating and $19 price target. World's leading producer of Styrenic Block Copolymers. 2010 and 2011 EPS estimates set at $1.74 and $1.79, respectively.
upgraded at BMO to Outperform. $25 price target. Operating profits appear to be accelerating at Victoria's Secret.
upgraded at Barclays to Overweight from Equal Weight on cost cutting. Price target raised to $34 from $26. 2009 and 2010 EPS estimates set at $2.75 and $2.80, respectively.
upgraded at Credit Suisse to Outperform from Neutral on improved outlook. Price target surged to $42 from $27. 2010 and 2011 EPS estimates set at $2.08 and $2.55, respectively.
downgraded at Morgan Stanley to Equal-weight. Stock is already beginning to price in Haynesville volume growth.
Sirius XM Radio
rated new Buy at Lazard. SIRI was initiated with a Buy rating. $1 price target. Company is raising prices and costs are falling. Financial strength is also improving.
upgraded at Argus from Hold to Buy. $60 price target. Expectations are low, and sales could recover in capital markets once again.
STOCK COMMENTS / EPS CHANGES
target, estimates raised at Credit Suisse. AAPL price target to $275 from $250 after posting a solid quarter. 2010 and 2011 EPS estimates set at $11.54 and $12.44, respectively. Outperform rating.
target, estimates higher at Barclays. AAPL target $5 to $265 after strong 1Q10 results. 2010 and 2011 EPS estimates raised to $11.60 and $12.75, respectively. Maintain Overweight rating.
estimates, target increased at Goldman. AAPL estimates were boosted through 2011. Higher Mac sales offset lower iPod unit volume. Neutral rating and new $230 price target.
estimates lowered at Goldman through 2012. Company is seeing lower sales. Buy rating and $67 price target.
( ATHR) estimates, target raised at FBR. Shares of ATHR now seen reaching $39. Estimates also increased, to reflect market share gains. Market Perform rating.
( CEPH) numbers upped at UBS. CEPH estimates were increased through 2010. Provigil price hike is paying off. Buy rating and new $72 price target.
numbers increased at Goldman. Shares of DGX now seen reaching $55. Estimates also raised, because of an expected stock buyback and improving debt collection trends. Sell rating.
estimates, target boosted at Citigroup. Shares of HAL now seen reaching $40. Estimates also raised, because of a recovery in North America. Buy rating.
added to Conviction Sell List at Goldman. $32 price target. See below-consensus growth because of higher input costs and increased competition.
estimates, target raised at UBS. Shares of MCD now seen reaching $72. Estimates also boosted, as the company appears to be gaining market share. Buy rating.
estimates upped at FBR. TXN estimates were increased through 2011. Company boosted guidance, and is likely taking market share. Outperform rating.
price target higher at Credit Suisse. VMW price target improved to $34.50 from $28.50 on solid 4Q09 results. 2010 and 2011 EPS estimates set at $1.14 and $1.26, respectively. Maintain Underperform rating.
estimates, target boosted at Goldman. Shares of VMW now seen reaching $49. Estimates also upped, to reflect increased IT spending, especially in servers. Neutral rating.
estimates cut at UBS. ZION estimates were lowered through 2011. Company is facing higher security losses and profitability will likely be pushed out. Sell rating and $10 price target.
This article was written by a staff member of TheStreet.com.